Pharmac today has announced a consultation
on widening access to the meningococcal B vaccine (branded
as Bexsero) which would give thousands of young people and
infants protection against meningococcal B disease. The
proposal would allow for its inclusion in the childhood
immunisation schedule.
“Following the budget
increase announced in May 2022, we are working our way
through our options for investment list,” says Pharmac’s
chief medical officer Dr David Hughes. “We are pleased to
be progressing this proposal for the meningococcal B vaccine
that could bring a new vaccine onto the childhood
immunisation schedule and better protect our children from
infectious diseases.
Pharmac is seeking feedback on
the proposal to fund the meningococcal B vaccine from 1
March 2023 for:
- children up to 12 months of age,
and a catch up programme for children from 13 to 59 months
of age (inclusive) to 31 August 2025 - people aged 13
to 25 years who are entering into or in their first year of
close-living situations, and a catch up programme for people
this age who are already living in close-living situations
to 28 February 2024.
Meningococcal disease can
lead to serious illnesses including meningitis (inflammation
of your brain membranes) and septicaemia (blood poisoning).
These illnesses can develop quickly over a few hours and can
cause severe disability or even death.
“Over the
past few years, the number of meningococcal B cases being
notified has been increasing and we want to acknowledge the
concern from the public and advocacy groups including the
Meningitis Foundation,” says Dr Hughes. “Meningococcal
disease can progress very rapidly, but vaccination can
provide protection for our children and young
adults.”
“If this proposal is approved, we
estimate that around 300,000 people would be eligible during
the catch-up period, and around 60,000 new infants and young
people each year following,” says Dr Hughes. “We are
aware that Māori and Pacific peoples have higher infection
rates than the total population, so this proposal is a step
towards improved protection for these
communities.”
Today Pharmac is also proposing to
secure the ongoing listing of the shingles vaccine (branded
as Shingrix). There are no proposed changes to eligibility
criteria as part of this proposal, but Pharmac has shared
recommendations on additional proposals from its clinical
advisors.
“Our clinical advisors have considered who
else would benefit from expanded access to the funded
shingles vaccine, including:
- people from 50 to 54
years of age - people over 65 years of age who have
received Zostavax at least 5 years previously - Māori
and Pacific peoples 60 years of age and
over.
“We are also assessing and seeking further
clinical advice on other groups that may benefit from
Shingrix, including:
- people who have immune
systems with reduced function - people over 65 years
of age who missed their zoster vaccination at 65 years of
age while there was reduced access to healthcare services
during the COVID-19 pandemic - people over 65 years of
age who are immunosuppressed and could not be vaccinated
with the previously funded shingles vaccine (Zostavax) when
they were 65 years of age.
“While we are not
currently consulting on these groups, we want to let people
know we are considering more evidence in this space,” says
Dr Hughes. “Anyone interested can learn more about the
assessment of these proposals, including links to the
relevant clinical advice, on the Application
Tracker.”
This consultation has been sent to
relevant health care professionals, patient groups and
others who Pharmac thinks would be interested. It is
available on the Pharmac website for anyone wanting to have
their say.
“Consultation is a very important step in
our process,” says Dr Hughes. “It’s how we check that
the people who will get the most benefit from the vaccines
they can access. If approved, we will also be working
closely with our colleagues across the health sector as they
plan for the implementation of these changes to the National
Immunisation
Schedule.”
© Scoop Media



















Discussion about this post